Influvac

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) and Influenza A/Vic, the active ingredient in Influvac, is a vaccine presented as an injectable solution for intramuscular and subcutaneous use. It is intended to induce immunity against seasonal influenza A and B viruses in individuals for whom vaccination is recommended.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable cold‑chain logistics for vaccine distribution through established global networks.

Influvac is a vaccine that targets seasonal influenza viruses to prevent infection. - Seasonal influenza: reduces the likelihood of acquiring influenza A and B infections. - High‑risk populations (elderly, chronic disease patients): provides added protection against severe influenza outcomes. - Community health programs: contributes to herd immunity and lowers overall influenza transmission.

Influvac may be associated with a range of post‑vaccination reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild soreness at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: temperature rise up to 38 °C. - Headache: mild to moderate head discomfort. - Myalgia: muscle aches lasting a day or two. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - High fever: temperature above 39 °C persisting more than 48 hours. - Seizures: uncommon convulsive episodes, especially in children. - Severe local reaction: extensive swelling or necrosis at injection site.

Before administering Influvac, healthcare professionals should consider the following precautions to ensure safe use. - Allergy assessment: verify no severe allergy to egg protein or vaccine components. - Post‑vaccination observation: monitor the patient for at least 15 minutes for immediate reactions. - Pregnancy considerations: discuss benefits and risks with a qualified healthcare provider. - Immunocompromised patients: vaccine may elicit a reduced immune response. - Acute illness: defer vaccination until the individual has recovered from moderate or severe febrile illness. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Influvac can interact with certain medical products or therapies; awareness of these interactions helps maintain vaccine effectiveness.

Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration within 4 weeks to prevent interference. - Immunoglobulin or blood products: may diminish antibody response if given within 2 weeks before or after vaccination. - Antiviral agents (e.g., oseltamivir): can reduce vaccine efficacy if administered within 48 hours of the vaccine.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: monitor antibody titres as response may be suboptimal. - Corticosteroids (systemic): may modestly lower immunogenicity, consider timing. - Febrile illness: vaccination during active fever may increase reactogenicity; assess risk‑benefit.